AndreaBozzo/ceres-open-data-index huggingface dataset:
Latent transforming growth factor β-binding protein-3 and fibulin-1C interact with the extracellular domain of the heparin-binding EGF-like growth factor precursor

Background
          The membrane-bound cell-surface precursor and soluble forms of heparin-binding epidermal growth factor-like growth factor (HB-EGF) contribute to many cellular developmental processes. The widespread occurrence of HB-EGF in cell and tissue types has led to observations of its role in such cellular and tissue events as tumor formation, cell migration, extracellular matrix formation, wound healing, and cell adherence. Several studies have reported the involvement of such extracellular matrix proteins as latent transforming growth factor β-binding protein, TGF-β, and fibulin-1 in some of these processes. To determine whether HB-EGF interacts with extracellular matrix proteins we used the extracellular domain of proHB-EGF in a yeast two-hybrid system to screen a monkey kidney cDNA library. cDNA clones containing nucleotide sequences encoding domains of two proteins were obtained and their derived amino acid sequences were evaluated.
        
        
          Results
          From ≈ 3 × 106 screened monkey cDNA clones, cDNA clones were recovered that contained nucleotide sequences encoding domains of the monkey latent transforming growth factor-β binding protein-3 (MkLTBP-3) and fibulin-1C protein. The amino acid sequence derived from the MkLTBP-3 gene shared 98.6% identity with human LTBP-3 and 86.7% identity with mouse LTBP-3 amino acid sequences. The amino acid sequence derived from the monkey fibulin-1C gene shared 97.2% identity with human fibulin-1C. Yeast two-hybrid screens indicate that LTBP-3 and fibulin-1C interact with proHB-EGF through their calcium-binding EGF-like modules.
        
        
          Conclusions
          The interactions of the extracellular domain of proHB-EGF with LTBP-3 and fibulin-1C suggest novel functions for HB-EGF between cell and tissue surfaces.
Articular cartilage and changes in Arthritis: Cell biology of osteoarthritis

The reaction patterns of chondrocytes in osteoarthritis can be summarized in five categories: (1) proliferation and cell death (apoptosis); changes in (2) synthetic activity and (3) degradation; (4) phenotypic modulation of the articular chondrocytes; and (5) formation of osteophytes. In osteoarthritis, the primary responses are reinitiation of synthesis of cartilage macromolecules, the initiation of synthesis of types IIA and III procollagens as markers of a more primitive phenotype, and synthesis of active proteolytic enzymes. Reversion to a fibroblast-like phenotype, known as 'dedifferentiation', does not appear to be an important component. Proliferation plays a role in forming characteristic chondrocyte clusters near the surface, while apoptosis probably occurs primarily in the calcified cartilage.
Information Memorandum (IM-89-09)

This Information Memorandum (IM) provides information on  FY 1989 allotments for Title IV-B and procedures for applying for:

1. A State's share of funds available under Title IV-B in FY 1989
2. Reallocated Title IV-B funds
3. Funds to be transferred from Title IV-E foster care.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 525507: Allyl isobutyl disulfide

Chemical compound data from PubChem database. IUPAC Name: 2-methyl-1-(prop-2-enyldisulfanyl)propane. Molecular Formula: C7H14S2. Molecular Weight: 162.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528031: Benzoic acid, 3,5-dinitro, 1-phenylethyl ester

Chemical compound data from PubChem database. IUPAC Name: 1-phenylethyl 3,5-dinitrobenzoate. Molecular Formula: C15H12N2O6. Molecular Weight: 316.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529396: 1-(5-Methyl-1,3-thiazol-2-yl)ethan-1-one

Chemical compound data from PubChem database. IUPAC Name: 1-(5-methyl-1,3-thiazol-2-yl)ethanone. Molecular Formula: C6H7NOS. Molecular Weight: 141.19. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528101: tert-Butyl(dimethyl)silyl propionate

Chemical compound data from PubChem database. IUPAC Name: [tert-butyl(dimethyl)silyl] propanoate. Molecular Formula: C9H20O2Si. Molecular Weight: 188.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 527602: 4-Penten-1-ol, trichloroacetate

Chemical compound data from PubChem database. IUPAC Name: pent-4-enyl 2,2,2-trichloroacetate. Molecular Formula: C7H9Cl3O2. Molecular Weight: 231.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E401254-T1: [Translated] DISPENSING CAP

The cap (10) consists of a lower mounting portion (1) fixed onto the container neck, an upper cover (2) containing the dispensing components e.g. valves, gas-proof sealing elements between cap and bottle, an outlet for pouring liquid and a tube support for a siphon structure. A removable fixing material (27) is provided for preventing dispensing of liquid if necessary.
Interferon beta-1a

Rebif (interferon beta-1a) is a prescription medication manufactured by EMD Serono, Inc., used to treat relapsing forms of multiple sclerosis (MS). It comes in prefilled syringes for subcutaneous injection in strengths of 22 mcg/0.5 mL and 44 mcg/0.5 mL. Approved in 2002 under BLA103780, it belongs to the interferon beta class of drugs. This information was generated using AI and is provided for informational and research purposes only.
Compound 527094: Citalopram, nor, acetyl

Chemical compound data from PubChem database. IUPAC Name: N-[3-[5-cyano-1-(4-fluorophenyl)-3H-2-benzofuran-1-yl]propyl]-N-methylacetamide. Molecular Formula: C21H21FN2O2. Molecular Weight: 352.4. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E400406-T1: [Translated] REVERSIBLE RATCHET TOOL WITH IMPROVED PAWL

A ratcheting tool (10) includes a body and a gear (48) disposed in the body. The gear defines a plurality of concave teeth (52) on a circumference of the gear so that the gear teeth define a first arc having a first radius (R1). A pawl (94) is disposed in the body so that the pawl is movable laterally with respect to the gear between a first position, in which the pawl is disposed between the body and the gear so that the body transmits torque through pawl in a first rotational direction, and a second position, in which the pawl is disposed between the body and the gear so that the body transmits torque through the pawl in an opposite rotational direction. The pawl defines a plurality of convex teeth facing the gear. A first arc extends between opposite axial ends of the gear and is defined by the gear's concave center area and a second arc between opposite sides of the pawl face and is defined by the pawl's convex center area, wherein a first radius (700) defined by the first arc is greater than a second radius (702) defined by the second arc.
Patent AT-E400681-T1: [Translated] POLYESTER YARN AND METHOD FOR PRODUCING SAME

The present invention relates to polyester yarn which is characterized in that it is a multifilament yarn substantially comprising polytrimethylene terephthalate, and as well as the strength from the stress-strain curve being at least 3 cN/dtex and the Young's modulus being no more than 25 cN/dtex, the minimum value of the differential Young's modulus at 3-10% extension is no more than 10 cN/dtex and the elastic recovery following 10% elongation is at least 90%. Furthermore, said polyester yarn can be obtained by a method of producing polyester yarn which is characterized in that multifilament yarn obtained by the melt spinning of polymer substantially comprising polytrimethylene terephthalate of intrinsic viscosity Ä eta Ü at least 0.7 is hauled-off at a spinning rate of at least 2000 m/min and, without winding up, subjected to drawing and heat-treatment, after which it is continuously subjected to a relaxation heat treatment at a relaxation factor of 6 to 20% and wound up as a package. Moreover, the present invention also relates to a woven material of outstanding soft-stretchability which is characterized in that the aforesaid polyester yarn is used as the warp yarn and/or the weft yarn in the form of twisted yarn of twist coefficient 10,000 to 20,000. In this way, it is possible to produce yarn stably at a high yarn production rate without package tightening occurring, and, as well as there being little variation in properties in the fibre lengthwise direction, when made into fabric, said fabric stretches at low modulus so there is little sense of tightness, and it is possible to provide polyester yarn and woven materials with a soft handle. <IMAGE>
Adoption Savings Data

Since federal fiscal year (FFY) 2010, the title IV-E Adoption Assistance program has provided expanded eligibility provisions for any child who meets the criteria for an “applicable child” as defined in section 473(e) of the Social Security Act (the Act). Use of the applicable-child eligibility provisions (section 473(a)(2)(A)(ii) of the Act) tends to result in more children being determined as eligible for title IV-E since it delinks eligibility for the title IV-E Adoption Assistance program from the requirements of the Aid to Families with Dependent Children program, among other changes. (See Program Instruction [PI] ACYF-CB-PI-09-10, dated August 26, 2009, for more details on the applicable-child eligibility criteria.) The increased eligibility allows states to receive additional federal funding for adoption, thereby allowing them to reduce the level of nonfederal funds they use for these services. The reduction in nonfederal spending is referred to as “adoption savings.”

Federal law (section 473(a)(8) of the Act) requires title IV-E agencies to spend an amount equal to any savings they achieve as a result of applying the differing program eligibility criteria to applicable children for other child welfare service activities permitted under titles IV-B or IV-E of the Act. The amount of adoption savings is calculated based on the title IV-E Adoption Assistance program claims made on behalf of those children who, absent the applicable-child eligibility criteria, would not have been determined eligible for title IV-E Adoption Assistance. The savings are generally equal to the federal share of these claims since, in most instances, that amount would otherwise have been paid from nonfederal title IV-E agency funds. A portion of the expenditures of adoption savings funds must be used for specified services.

To implement the adoption savings requirements, the Children’s Bureau (CB) issued PIs providing detailed guidance on the calculation, expenditure, and reporting of adoption savings and developed a new annual reporting form (CB-496 Part 4) to collect the information. See PIs ACYF-CB-PI-15-06 and ACYF-CB-PI-21-08 for details on these instructions.

Title IV-E agencies—as of FFY 2015—are required to calculate and report annually their adoption savings, the methodology used to calculate the savings, how savings are spent, and on what services. In calculating adoption savings, title IV-E agencies must use a methodology specified by CB or may propose an alternative for approval. The methodology developed and issued by CB is referred to as “the CB Method.” This method can be applied either to a sample of cases or to the full universe of cases if the agency was able to access actual figures for needed information without conducting a special review. The statute also requires that the annual adoption savings information reported by state and tribal title IV-E agencies be posted on the CB website.

Metadata-only record linking to the original dataset. Open original dataset below.
Compound 528769: Tricyclo[5.2.1.0(2.6)]dec-3-ene, 3-methyl-8-methylene

Chemical compound data from PubChem database. IUPAC Name: 3-methyl-8-methylidenetricyclo[5.2.1.02,6]dec-3-ene. Molecular Formula: C12H16. Molecular Weight: 160.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528407: 5-Ethyl-2-methyloxazole

Chemical compound data from PubChem database. IUPAC Name: 5-ethyl-2-methyl-1,3-oxazole. Molecular Formula: C6H9NO. Molecular Weight: 111.14. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525133: alpha-D-Glucopyranoside, 2,3,4,6-tetra-O-methyl-alpha-D-glucopyranosyl 2,3,4,6-tetra-O-methyl-

Chemical compound data from PubChem database. IUPAC Name: 3,4,5-trimethoxy-2-(methoxymethyl)-6-[3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxyoxane. Molecular Formula: C20H38O11. Molecular Weight: 454.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Reporting of conflicts of interest in guidelines of preventive and therapeutic interventions

Background
          Guidelines published in major medical journals are very influential in determining clinical practice. It would be essential to evaluate whether conflicts of interests are disclosed in these publications. We evaluated the reporting of conflicts of interest and the factors that may affect such disclosure in a sample of 191 guidelines on therapeutic and/or preventive measures published in 6 major clinical journals (Annals of Internal Medicine, BMJ, JAMA, Lancet, New England Journal of Medicine, Pediatrics) in 1979, 1984, 1989, 1994 and 1999.
        
        
          Results
          Only 7 guidelines (3.7%) mentioned conflicts of interest and all were published in 1999 (17.5% (7/40) of guidelines published in 1999 alone). Reporting of conflicts of interest differed significantly by journal (p=0.026), availability of disclosure policy by the journal (p=0.043), source of funding (p < 0.001) and number of authors (p=0.004). In the entire database of 191 guidelines, a mere 18 authors disclosed a total of 24 potential conflicts of interest and most pertained to minor issues.
        
        
          Conclusions
          Despite some recent improvement, reporting of conflicts of interest in clinical guidelines published in influential journals is largely neglected.
The effect of continuous positive airway pressure (CPAP) on renal
		  vascular resistance: the influence of renal denervation

Objective:
          To non-invasively study the effects of continuous positive airway
				pressure breathing (CPAP) on renal vascular resistance in normal subjects and
				renal allograft recipients, in other words those with with denervated kidneys.
				We could then ascertain the influence of renal innervation on any resulting
				changes in renal haemodynamics.
        
        
          Methods:
          Ten healthy volunteers and six renal transplant patients were
				studied. Using Doppler ultrasonography, the pulsatility index (PI), an index of
				renovascular resistance, was measured at incremental levels of CPAP (0, 2.5,
				5.0 and 7.5 cmH2O).
        
        
          Results:
          In both groups, the PI increased significantly between 0 and
          5.0 cmH2O CPAP, with a further increase at 7.5 cmH2O CPAP.
        
        
          Conclusions:
          We found that CPAP at 5.0 and 7.5 cmH2O caused a
				significant increase in renovascular resistance in both normal and renal
				transplant patients. There was no difference in the degree of rise in
				renovascular resistance between both groups, indicating that the renal nerves
				do not play a role in altering renal vascular resistance with the application
				of CPAP.
Compound 527698: Butanoic acid, 4-chloro, 1-methyl-3-butenyl ester

Chemical compound data from PubChem database. IUPAC Name: pent-4-en-2-yl 4-chlorobutanoate. Molecular Formula: C9H15ClO2. Molecular Weight: 190.67. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Newborn Screening Disorders

This dataset contains three tables of aggregated (2009-2019) data on newborn screening disorders: 1) counts statewide , 2) counts by race/ethnicity, 3) counts by California region.  The tables present counts of disorders that have been diagnosed by the California Newborn Screening Program. Counts were suppressed for disorders with fewer than 6 cases, as described in the individual table descriptions.

The disorders are included on the core Recommended Uniform Screening Panel (RUSP) put forth by the Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC) established under Section 1111 of the Public Health Service (PHS) Act, 42 U.S.C. 300b-10, as amended in the Newborn Screening Saves Lives Act of 2008. The SACHDNC recommends that every state newborn screening program include a uniform screening panel that currently includes 33 core disorders. The Newborn Screening Program screens for all of the core conditions except Spinal Muscular Atrophy, which began in June 2020. Newborn hearing loss screening and critical congenital heart disease screening are programs administered by the California Department of Health Care Services. Details of the disorders included on the RUSP can be found in the attachment: Recommended Uniform Screening Panel.pdf.

Caution must be taken in interpreting these data because there is not a one-to-one relationship between a screen-positive test result and a disorder. A newborn can be screen-positive for more than one disorder. Conversely, a positive screen for one disorder can be associated with the diagnosis of a different disorder. Four types of sickle cell-related hemoglobinopathies (Sickle Beta0 Thalassemia, Sickle Beta+ Thalassemia, Sickle S/S Disease, and Sickle S/C Disease) were combined into one group called "Sickle Cell Disease." SCID cases are reported beginning March 2013. ALD cases are reported beginning February 2016. Pompe and MPS I cases are reported beginning August 2018.
Compound 528317: Pyrazine, 3-ethylthio-2-pentyl

Chemical compound data from PubChem database. IUPAC Name: 2-ethylsulfanyl-3-pentylpyrazine. Molecular Formula: C11H18N2S. Molecular Weight: 210.34. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 528902: 5-Ethyl-5-(4-acetoxyphenyl)-hexahydropyrimidin-2,4,6-trione

Chemical compound data from PubChem database. IUPAC Name: [4-(5-ethyl-2,4,6-trioxo-1,3-diazinan-5-yl)phenyl] acetate. Molecular Formula: C14H14N2O5. Molecular Weight: 290.27. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 529171: 1-Pentanamine, bis-TMS

Chemical compound data from PubChem database. IUPAC Name: N,N-bis(trimethylsilyl)pentan-1-amine. Molecular Formula: C11H29NSi2. Molecular Weight: 231.52. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530206: o-Methoxymandelic acid, trimethylsiloxy-, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(2-methoxyphenyl)-2-trimethylsilyloxyacetate. Molecular Formula: C15H26O4Si2. Molecular Weight: 326.53. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Effects of Cu

Background
          Heavy metals, especially copper, nickel, lead and zinc, have adverse effects on terrestrial and in aquatic environments. However, their impact can vary depending on the nature of organisms. Taking into account the ability of heavy metals to accumulate in sediments, extended knowledge of their effects on aquatic biota is needed. In this context the use of model organisms (often unicellular), which allows for rapid assessment of pollutants in freshwater, can be of advantage. Pentachlorophenol has been extensively used for decades as a bleaching agent by pulp- and paper industry. Pentachlorophenol tends to accumulate in the nature. We aim to determine if photosynthesis and motility can be used as sensitive physiological parameters in toxicological studies of Chlamydomonas reinhardtii, a motile green unicellular alga. It is discussed if photosynthesis and motility can be used as sensitive physiological parameters in toxicological studies.
        
        
          Results
          The concentrations studied ranged from 0.1 to 2.0 mg l-1 for copper, nickel, lead and zinc, and from 0.1 to 10.0 mg l-1 for pentachlorophenol. Exposure time was set to 24 h. Copper and pentachlorophenol turned out to be especially toxic for photosynthetic efficiency (PE) in C. reinhardtii.
        
        
          Conclusion
          Copper and pentachlorophenol turned out to be especially toxic for PE in C. reinhardtii. Zinc has been concluded to be moderately toxic while nickel and lead had stimulatory effects on the PE. Because of high variance, motility was not considered a reliable physiological parameter when assessing toxicity of the substances using C. reinhardtii.
Compound 525522: 3-(4-Methoxy-phenyl)-2-methyl-propionic acid, methyl ester

Chemical compound data from PubChem database. IUPAC Name: methyl 3-(4-methoxyphenyl)-2-methylpropanoate. Molecular Formula: C12H16O3. Molecular Weight: 208.25. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Pro/con clinical debate: The use of a protected specimen brush in the diagnosis of ventilator associated pneumonia

Although mechanical ventilation is instituted as a life-saving technique, it may lead to complications that can negatively impact on patients' morbidity and/or mortality. Ventilator associated pneumonia (VAP) is one such complication that is a common challenge to intensivists. Although most experts would agree that early 'appropriate' antibiotic use is essential in patients who develop VAP, the best diagnostic test to guide decision-making is far from clear. One diagnostic test that is capable of providing microbiological samples from the lower respiratory tree is invasive bronchoscopy with a protected specimen brush. Such a procedure has long been available to intensivists and is frequently employed in many intensive care units. However, this procedure has associated costs and potential complications, and its utility in VAP has been challenged. In this issue of Critical Care Forum, the two sides of this debate are brought forward with compelling arguments. The authors' arguments should fuel future trials.